Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novo Nordisk |
---|---|
Information provided by: | Novo Nordisk |
ClinicalTrials.gov Identifier: | NCT00655044 |
This study is conducted in Europe.
The aim of this observational study is to evaluate the incidence of serious adverse drug reactions while using Levemir® under normal clinical practice conditions.
Condition | Intervention |
---|---|
Diabetes Mellitus |
Drug: insulin detemir |
Study Type: | Observational |
Study Design: | Case Control |
Official Title: | Observational, Safety Study in Subjects Using Levemir® (Insulin Detemir) for the Treatment of Type 1 or Type 2 Diabetes Mellitus |
Estimated Enrollment: | 3945 |
Study Start Date: | May 2007 |
Study Completion Date: | January 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Groups/Cohorts | Assigned Interventions |
---|---|
A
Type 1 and type 2 diabetes patients
|
Drug: insulin detemir
Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Type 1 and type 2 diabetes patients
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Novo Nordisk A/S ( Public Access to Clinical Trials ) |
Study ID Numbers: | NN304-3514 |
Study First Received: | April 4, 2008 |
Last Updated: | October 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00655044 |
Health Authority: | Russia: Federal Service for Control of Health Care and Social Developme |
Metabolic Diseases Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Metabolic disorder Glucose Metabolism Disorders Insulin |
Hypoglycemic Agents Physiological Effects of Drugs Pharmacologic Actions |